Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma
Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma
复制标题
膀胱尿路上皮癌患者免疫相关风险特征的发展
DOI：
10.1155/2020/5848493
复制
发表时间：
2020-08-20
影响因子：
--
通讯作者：
Liang, Bo
中科院分区：
文献类型：
--
作者：
Jiang, Yaofei;Wang, Yibing;Liang, Bo
随着近年来免疫肿瘤学和肿瘤微环境研究的进展，膀胱尿路上皮癌的治疗前景发生了巨大的变化。我们的目标是构建一个免疫基因相关的特征，可以预测BLCA患者的总生存期。从The Cancer Genome Atlas数据库下载BLCA患者的转录组学数据，从Immunology database和Analysis Portal数据库下载免疫相关基因。鉴定预后免疫相关基因。然后，我们构建并验证了一个免疫基因相关的签名。从Cistrome数据库中下载肿瘤相关转录因子，并生成它们与预后免疫相关基因之间的网络。采用Cox比例风险模型和Kaplan-Meier生存分析来评估我们的签名的预后能力。探讨其与患者临床病理特征的关系，验证其临床价值。我们进一步从肿瘤免疫估计资源数据库中下载了六种免疫细胞的浓度，以探索该特征的免疫相关潜在机制。
With recent advances in immunooncology and tumor microenvironment, the treatment landscape of bladder urothelial carcinoma has been changing dramatically. We aim to construct an immune gene-related signature which can predict BLCA patients' overall survival. Transcriptomic data of BLCA patients was downloaded from The Cancer Genome Atlas database, and immune-related genes were downloaded from the Immunology Database and Analysis Portal database. Prognostic immune-related genes were identified. We then constructed and validated an immune gene-related signature. Tumor-related transcription factors were downloaded from the Cistrome database, and a network between them and prognostic immune-related genes was generated. Cox's proportional hazards model and the Kaplan–Meier survival analysis were performed to assess our signature's prognostic ability. Relationship between the signature and patients' clinicopathologic features was then explored to validate its clinical value. We further downloaded concentration of six types of immune cells from the Tumor Immune Estimation Resource database to explore immune-related potential mechanisms of the signature.